Previous 10 | Next 10 |
ATLANTA, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Milestone Pharmaceuticals Inc. (“Milestone Pharmaceuticals” or the “Company”) (NASDAQ: MIST) complied with federal securities laws. On December 26, 2023, the Company disc...
2023-12-26 13:19:25 ET Gainers: RayzeBio ( RYZB ) +101% . IMAC Holdings ( BACK ) +73% . Bit Brother Limited ( BETS ) +63% . Gracell Biotechnological ( GRCL ) +60% . Volcon ( VLCN ) +54% . Sight Sciences ( SGHT ) +45% ...
BOSTON, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about ...
2023-12-26 10:02:19 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...
2023-12-26 08:29:35 ET Losers: Alternus Clean Energy ( ALCE ) -42% . LeddarTech Holdings ( LDTC ) -27% . Milestone Pharmaceuticals ( MIST ) -28% receives refusal to file letter from U.S. FDA for new drug application for Etripamil in the treatment of...
2023-12-26 07:33:20 ET More on Milestone Pharmaceuticals Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals Historical earnings data for Milestone Pharmaceuticals Financial information for Milestone Pharmaceuticals For further details see: M...
MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-admin...
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Nov. 21, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its manageme...
2023-11-13 06:58:59 ET More on Milestone Pharmaceuticals Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals Historical earnings data for Milestone Pharmaceuticals Financial information for Milestone Pharmaceuticals For further details see: M...
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates Canada NewsWire New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST ™ , the conditionally approved brand name f...
News, Short Squeeze, Breakout and More Instantly...
Milestone Pharmaceuticals Inc. Company Name:
MIST Stock Symbol:
NYSE Market:
Milestone Pharmaceuticals Inc. Website:
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will host Part I of its virtual investor educ...
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024. ...
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug A...